Research programme: IL1RAP antibody therapeutics - Cantargia

Drug Profile

Research programme: IL1RAP antibody therapeutics - Cantargia

Alternative Names: CAN 04; CANxx

Latest Information Update: 06 Apr 2017

Price : $50

At a glance

  • Originator Lund University
  • Developer Cantargia
  • Class Monoclonal antibodies
  • Mechanism of Action Membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chronic myeloid leukaemia; Solid tumours
  • Research Autoimmune disorders; Inflammation

Most Recent Events

  • 05 Apr 2017 Cantargia receives an Intention to Grant Notice from the European Patent Office for its patent application for CAN 04
  • 20 Oct 2016 Pharmacodynamics data from preclinical studies in Solid tumours (Non small cell lung cancer) released by Cantargia
  • 23 Sep 2016 CAN 04 is still in preclinical development for Chronic myeloid leukaemia in Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top